Rhopressa - (0.02% ; Ophthalmic solution)

Generic Name	Netarsudil Mesylate	Innovator	Aerie pharma
Dosage	0.02% ; Ophthalmic solution	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	Less Than 5	Generic Launches	None
Indication	RHOPRESSA® (netarsudil ophthalmic solution) 0.02% is a Rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
***** ******	*** / *********	**** **, ****	******* / ********* ****	********	******* *** **** *** *** ****
*********	*** / ***	**** **, ****	*******	********* ********	******* *** **** *** *** ****

Chronology Of Events